<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Your-Story.org &#187; Biotech</title>
	<atom:link href="http://your-story.org/category/science-technology/biotech/feed/" rel="self" type="application/rss+xml" />
	<link>http://your-story.org</link>
	<description>The Press Release Resource</description>
	<lastBuildDate>Tue, 14 Feb 2012 21:18:37 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Biotage (STO: BIOT) Introduces SNAP Ultra High Performance Flash Chromatography Cartridges with Biotage HP-Sphere Silica</title>
		<link>http://your-story.org/biotage-sto-biot-introduces-snap-ultra-high-performance-flash-chromatography-cartridges-with-biotage-hp-sphere-silica-308811/</link>
		<comments>http://your-story.org/biotage-sto-biot-introduces-snap-ultra-high-performance-flash-chromatography-cartridges-with-biotage-hp-sphere-silica-308811/#comments</comments>
		<pubDate>Tue, 14 Feb 2012 21:17:40 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[cartridges]]></category>
		<category><![CDATA[flash chromatography cartridges]]></category>
		<category><![CDATA[silica]]></category>
		<category><![CDATA[snap ultra]]></category>
		<category><![CDATA[STO: BIOT]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=308811</guid>
		<description><![CDATA[Biotage introduced the new Biotage® SNAP Ultra high performance flash chromatography cartridges utilizing Biotage® HP-Sphere™ spherical silica. Uppsala, Sweden, February 14, 2012 &#8212; Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced the new Biotage® SNAP Ultra high performance flash chromatography cartridges utilizing Biotage® HP-Sphere™ spherical silica. ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-sto-biot-introduces-snap-ultra-high-performance-flash-chromatography-cartridges-with-biotage-hp-sphere-silica-308811/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech stocks News; BioSante Pharmaceuticals (NasdaqGM: BPAX) Reports Positive LibiGel® Safety Data Review for Phase III Program</title>
		<link>http://your-story.org/biotech-stocks-news-biosante-pharmaceuticals-nasdaqgm-bpax-reports-positive-libigel-safety-data-review-for-phase-iii-program-307783/</link>
		<comments>http://your-story.org/biotech-stocks-news-biosante-pharmaceuticals-nasdaqgm-bpax-reports-positive-libigel-safety-data-review-for-phase-iii-program-307783/#comments</comments>
		<pubDate>Fri, 10 Feb 2012 08:26:27 +0000</pubDate>
		<dc:creator>Investorideas</dc:creator>
				<category><![CDATA[Biotech]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=307783</guid>
		<description><![CDATA[LINCOLNSHIRE, Ill. &#8211; February 9, 2012 (Investorideas.com Newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study ...]]></description>
		<wfw:commentRss>http://your-story.org/biotech-stocks-news-biosante-pharmaceuticals-nasdaqgm-bpax-reports-positive-libigel-safety-data-review-for-phase-iii-program-307783/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech Stock on the Move: BioSante (NasdaqGM: BPAX) Trades up over 37%</title>
		<link>http://your-story.org/biotech-stock-on-the-move-biosante-nasdaqgm-bpax-trades-up-over-37-306735/</link>
		<comments>http://your-story.org/biotech-stock-on-the-move-biosante-nasdaqgm-bpax-trades-up-over-37-306735/#comments</comments>
		<pubDate>Mon, 06 Feb 2012 21:13:05 +0000</pubDate>
		<dc:creator>Investorideas</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[stocks]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=306735</guid>
		<description><![CDATA[New York, New York – February 6, 2012 &#8211; Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for BioSante Pharmaceuticals, Inc. (NasdaqGM: BPAX), trading up at $1.0199, gaining 0.2799 (37.82%) 3:10PM EST. The Company has rebounded from its low of $0.38, now trading above $1.00 ...]]></description>
		<wfw:commentRss>http://your-story.org/biotech-stock-on-the-move-biosante-nasdaqgm-bpax-trades-up-over-37-306735/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech Stock to Watch: Complete Genomics (Nasdaq:GNOM) Trades up over 15%</title>
		<link>http://your-story.org/biotech-stock-to-watch-complete-genomics-nasdaqgnom-trades-up-over-15-306716/</link>
		<comments>http://your-story.org/biotech-stock-to-watch-complete-genomics-nasdaqgnom-trades-up-over-15-306716/#comments</comments>
		<pubDate>Mon, 06 Feb 2012 17:28:47 +0000</pubDate>
		<dc:creator>Investorideas</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[stocks]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=306716</guid>
		<description><![CDATA[New York, New York &#8211; February 6, 2012 &#8211; Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Complete Genomics Inc. (Nasdaq:GNOM). The stock is trading up at $3.46, gaining 0.45 (14.95%) 11:03AM EST on over 1.7 Million shares. Investorideas.com Newswire About Complete Genomics (Nasdaq:GNOM) ...]]></description>
		<wfw:commentRss>http://your-story.org/biotech-stock-to-watch-complete-genomics-nasdaqgnom-trades-up-over-15-306716/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Releases New Catalog and Technical Guide for Sample Preparation and Evaporation</title>
		<link>http://your-story.org/biotage-releases-new-catalog-and-technical-guide-for-sample-preparation-and-evaporation-304119/</link>
		<comments>http://your-story.org/biotage-releases-new-catalog-and-technical-guide-for-sample-preparation-and-evaporation-304119/#comments</comments>
		<pubDate>Sat, 28 Jan 2012 08:55:34 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[2012 catalog]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[Catalog]]></category>
		<category><![CDATA[new catalog]]></category>
		<category><![CDATA[sample preparation]]></category>
		<category><![CDATA[technical guide]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=304119</guid>
		<description><![CDATA[Biotage® introduced their 2012 catalog of analytical sample preparation products for chemistry professionals. Uppsala, Sweden, January 28, 2012 &#8212; Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced their 2012 catalog of analytical sample preparation products for chemistry professionals. The significantly enhanced 200 page edition includes a ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-releases-new-catalog-and-technical-guide-for-sample-preparation-and-evaporation-304119/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GenScript Launches Rush Gene Synthesis Service</title>
		<link>http://your-story.org/genscript-launches-rush-gene-synthesis-service-295992/</link>
		<comments>http://your-story.org/genscript-launches-rush-gene-synthesis-service-295992/#comments</comments>
		<pubDate>Tue, 27 Dec 2011 21:51:00 +0000</pubDate>
		<dc:creator>blueoxygen</dc:creator>
				<category><![CDATA[Biotech]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=295992</guid>
		<description><![CDATA[PISCATAWAY, N.J., Dec 22, 2011 &#8211; Internationally recognized biology contract research organization GenScript USA Inc. today announced the launch of Rush Gene Synthesis service in global market. As the largest gene synthesis supplier worldwide, GenScript is dedicated to improve the quality and speed of gene synthesis by developing and applying innovative technologies. With the Rush ...]]></description>
		<wfw:commentRss>http://your-story.org/genscript-launches-rush-gene-synthesis-service-295992/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech Investor Alert for (OTC: AEMD), (Nasdaq:VRUS), (VRTX); Hepatitis C Virus (HCV) Treatments</title>
		<link>http://your-story.org/biotech-investor-alert-for-otc-aemd-nasdaqvrus-vrtx-hepatitis-c-virus-hcv-treatments-288961/</link>
		<comments>http://your-story.org/biotech-investor-alert-for-otc-aemd-nasdaqvrus-vrtx-hepatitis-c-virus-hcv-treatments-288961/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 15:35:47 +0000</pubDate>
		<dc:creator>Investorideas</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[stocks]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=288961</guid>
		<description><![CDATA[POINT ROBERTS &#8211; November 28, 2011 &#8211; www.InvestorIdeas.com issues a biotech investor alert for Pharmasset, Inc. (Nasdaq:VRUS), Vertex Pharmaceuticals (VRTX) and Aethlon Medical, Inc. (OTCBB: AEMD), three stocks involved in the treatment of Hepatitis C Virus (HCV). &#160; Over 170 million people worldwide are chronically infected with Hepatitis C. The sector made headlines earlier this ...]]></description>
		<wfw:commentRss>http://your-story.org/biotech-investor-alert-for-otc-aemd-nasdaqvrus-vrtx-hepatitis-c-virus-hcv-treatments-288961/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Introduces First Value-Priced, Full-Featured Flash Purification System</title>
		<link>http://your-story.org/biotage-introduces-first-value-priced-full-featured-flash-purification-system-284432/</link>
		<comments>http://your-story.org/biotage-introduces-first-value-priced-full-featured-flash-purification-system-284432/#comments</comments>
		<pubDate>Thu, 10 Nov 2011 23:02:50 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[biotage zip]]></category>
		<category><![CDATA[flash cartridges]]></category>
		<category><![CDATA[flash purification system]]></category>
		<category><![CDATA[isolera prime]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=284432</guid>
		<description><![CDATA[Biotage® (STO: BIOT), a leading manufacturer of tools and technology for medicinal, organic, and analytical chemistry, introduced the new Isolera PrimeTM flash purification system. Uppsala, Sweden &#8211; November 10, 2011 &#8212; Biotage® (STO: BIOT), a leading manufacturer of tools and technology for medicinal, organic, and analytical chemistry, introduced the new Isolera PrimeTM flash purification system. ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-introduces-first-value-priced-full-featured-flash-purification-system-284432/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PREMIER Biosoft Releases SimGlycan® 3.50 with Support for Multiple Adducts.</title>
		<link>http://your-story.org/premier-biosoft-releases-simglycan%c2%ae-3-50-with-support-for-multiple-adducts-283816/</link>
		<comments>http://your-story.org/premier-biosoft-releases-simglycan%c2%ae-3-50-with-support-for-multiple-adducts-283816/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 09:45:48 +0000</pubDate>
		<dc:creator>Neilwatson</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[MS data analysis tool]]></category>
		<category><![CDATA[PREMIER Biosoft]]></category>
		<category><![CDATA[Structural elucidation of glycans]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=283816</guid>
		<description><![CDATA[Palo Alto, California – 9 November, 2011, PREMIER Biosoft today announced the release of a new version of SimGlycan®, its comprehensive, high throughput multi-stage MS data analysis tool. The program now includes support for adducts such as Li and K. Additionally, SimGlycan® 3.50 enables users to analyze MSn profiles using adduct combinations such as Na ...]]></description>
		<wfw:commentRss>http://your-story.org/premier-biosoft-releases-simglycan%c2%ae-3-50-with-support-for-multiple-adducts-283816/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Introduces Automated SPE Workstation for Increasing Productivity in Sample Preparation</title>
		<link>http://your-story.org/biotage-introduces-automated-spe-workstation-for-increasing-productivity-in-sample-preparation-278905/</link>
		<comments>http://your-story.org/biotage-introduces-automated-spe-workstation-for-increasing-productivity-in-sample-preparation-278905/#comments</comments>
		<pubDate>Wed, 19 Oct 2011 18:49:43 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[rapidtrace]]></category>
		<category><![CDATA[sample preparation]]></category>
		<category><![CDATA[spe workstation]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=278905</guid>
		<description><![CDATA[Biotage&#174; introduced the new RapidTrace&#174;+ SPE Workstation. RapidTrace+ is based on the widely accepted, industry standard RapidTrace platform. Uppsala, Sweden &#8211; October 18, 2011 &#8212; Biotage&#174; (STO: BIOT), a leading manufacturer of tools and technology for analytical and medicinal chemistry, introduced the new RapidTrace&#174;+ SPE Workstation. RapidTrace+ is based on the widely accepted, industry standard ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-introduces-automated-spe-workstation-for-increasing-productivity-in-sample-preparation-278905/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GenScript sued GeneWiz for unfair competition</title>
		<link>http://your-story.org/genscript-sued-genewiz-for-unfair-competition-277312/</link>
		<comments>http://your-story.org/genscript-sued-genewiz-for-unfair-competition-277312/#comments</comments>
		<pubDate>Thu, 13 Oct 2011 20:24:21 +0000</pubDate>
		<dc:creator>blueoxygen</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[gene synthesis]]></category>
		<category><![CDATA[GeneWiz]]></category>
		<category><![CDATA[GenScript]]></category>
		<category><![CDATA[trade secret]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=277312</guid>
		<description><![CDATA[PISCATAWAY, N.J., Sep 15, 2011 &#8211; GenScript USA, Inc. filed in New Jersey court a law suit against GeneWiz Inc. for misappropriation of trade secret and unfair competition. GenScript will seek compensatory damages, permanent injunctions, and other remedies from GeneWiz. &#160; GenScript USA, Inc. is a leading contract research organization (CRO) specialized in biological research ...]]></description>
		<wfw:commentRss>http://your-story.org/genscript-sued-genewiz-for-unfair-competition-277312/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CSHL Team Finds Evidence For The Genetic Basis Of Autism</title>
		<link>http://your-story.org/cshl-team-finds-evidence-for-the-genetic-basis-of-autism-276764/</link>
		<comments>http://your-story.org/cshl-team-finds-evidence-for-the-genetic-basis-of-autism-276764/#comments</comments>
		<pubDate>Wed, 12 Oct 2011 15:30:31 +0000</pubDate>
		<dc:creator>pressreleasesolutions</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Science]]></category>
		<category><![CDATA[Autism]]></category>
		<category><![CDATA[chromosome engineering]]></category>
		<category><![CDATA[Genetic Basis Of Autism]]></category>
		<category><![CDATA[Models of autism]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=276764</guid>
		<description><![CDATA[Models of autism show that gene copy number controls brain structure and behavior. Cold Spring Harbor, N.Y &#8211; October 12, 2011 &#8212; Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered that one of the most common genetic alterations in autism—deletion of a 27-gene cluster on chromosome 16—causes autism-like features. By generating mouse models of ...]]></description>
		<wfw:commentRss>http://your-story.org/cshl-team-finds-evidence-for-the-genetic-basis-of-autism-276764/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Engineering Next-Generation Therapeutic Proteins: Trends and Markets To 2020</title>
		<link>http://your-story.org/engineering-next-generation-therapeutic-proteins-trends-and-markets-to-2020-263437/</link>
		<comments>http://your-story.org/engineering-next-generation-therapeutic-proteins-trends-and-markets-to-2020-263437/#comments</comments>
		<pubDate>Sat, 27 Aug 2011 14:05:29 +0000</pubDate>
		<dc:creator>InsightPharmaReports</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Antibodies]]></category>
		<category><![CDATA[biological drugs]]></category>
		<category><![CDATA[life sciences]]></category>
		<category><![CDATA[market reports]]></category>
		<category><![CDATA[Market Research]]></category>
		<category><![CDATA[monoclonal antibodies]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[protein engineering]]></category>
		<category><![CDATA[proteins]]></category>
		<category><![CDATA[Therapeutic Proteins]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=263437</guid>
		<description><![CDATA[NEEDHAM, MASS. – August 26, 2011 – Cambridge Healthtech Institute’s Insight Pharma Reports announces the Engineering Next-Generation Therapeutic Proteins: Trends and Markets To 2020 Report, Authored by Hermann Mucke, PhD. By 2020, the current renaissance of biotechnology will have resulted in a broad range of products that will, almost without exception, involve a degree of ...]]></description>
		<wfw:commentRss>http://your-story.org/engineering-next-generation-therapeutic-proteins-trends-and-markets-to-2020-263437/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Insight Pharma Reports Announces: Next Generation Sequencing Generates Momentum</title>
		<link>http://your-story.org/insight-pharma-reports-announces-next-generation-sequencing-generates-momentum-263436/</link>
		<comments>http://your-story.org/insight-pharma-reports-announces-next-generation-sequencing-generates-momentum-263436/#comments</comments>
		<pubDate>Sat, 27 Aug 2011 14:05:17 +0000</pubDate>
		<dc:creator>InsightPharmaReports</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[bioinformatics]]></category>
		<category><![CDATA[life sciences]]></category>
		<category><![CDATA[market reports]]></category>
		<category><![CDATA[Market Research]]></category>
		<category><![CDATA[next generation sequencing]]></category>
		<category><![CDATA[NGS]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[sequencing]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=263436</guid>
		<description><![CDATA[NEEDHAM, MASS. – August 26, 2011 – Cambridge Healthtech Institute’s Insight Pharma Reports announces the Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances Report, Authored by Ken Rubenstein, PhD. This report focuses on current and innovative NGS technologies, services and markets to answer such questions as; •Which early NGS market entrants ...]]></description>
		<wfw:commentRss>http://your-story.org/insight-pharma-reports-announces-next-generation-sequencing-generates-momentum-263436/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Portal Gives Investors Carbon Market Insights</title>
		<link>http://your-story.org/new-portal-gives-investors-carbon-market-insights-259959/</link>
		<comments>http://your-story.org/new-portal-gives-investors-carbon-market-insights-259959/#comments</comments>
		<pubDate>Fri, 12 Aug 2011 09:17:19 +0000</pubDate>
		<dc:creator>smartebusiness1</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[carbon]]></category>
		<category><![CDATA[global carbon market]]></category>
		<category><![CDATA[market]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=259959</guid>
		<description><![CDATA[LONDON (August 9, 2011) &#8211; Invezz, one of UK&#8217;s up-and-coming boutique digital media companies, introduced today theirnewly launchedinvestments information portal, Carbon Markets (www.carbon-markets.co.uk). The website is designed to provide large corporations, small businesses and environmentally conscious individuals with valuable insights on the state, trends and forecasts of the dynamic carbon markets. &#8220;Carbon investments havebeen slowly ...]]></description>
		<wfw:commentRss>http://your-story.org/new-portal-gives-investors-carbon-market-insights-259959/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Online Educational Webinar to Explain Systolic and Diastolic Function in Rodent Models of Metabolic Syndrome</title>
		<link>http://your-story.org/online-educational-webinar-to-explain-systolic-and-diastolic-function-in-rodent-models-of-metabolic-syndrome-253971/</link>
		<comments>http://your-story.org/online-educational-webinar-to-explain-systolic-and-diastolic-function-in-rodent-models-of-metabolic-syndrome-253971/#comments</comments>
		<pubDate>Tue, 19 Jul 2011 14:15:58 +0000</pubDate>
		<dc:creator>scisense</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Adinstruments]]></category>
		<category><![CDATA[cardiac contractility]]></category>
		<category><![CDATA[cardiac function]]></category>
		<category><![CDATA[millar]]></category>
		<category><![CDATA[pressure-volume]]></category>
		<category><![CDATA[pressure-volume loop]]></category>
		<category><![CDATA[solid state pressure sensor]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=253971</guid>
		<description><![CDATA[For Immediate Release July, 18, 2011 &#8211; Scisense Systems Inc. hosts Dr. DeMarco from the University of Missouri. Dr. DeMarco will give an overview and summary of the PV loop data from transgenic Ren2 and Zucker obese rat models. Furthermore, he will review the results describing the cardiac dysfunction and address some of the technicalities ...]]></description>
		<wfw:commentRss>http://your-story.org/online-educational-webinar-to-explain-systolic-and-diastolic-function-in-rodent-models-of-metabolic-syndrome-253971/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Young mum is a science star</title>
		<link>http://your-story.org/young-mum-is-a-science-star-252875/</link>
		<comments>http://your-story.org/young-mum-is-a-science-star-252875/#comments</comments>
		<pubDate>Thu, 14 Jul 2011 11:32:03 +0000</pubDate>
		<dc:creator>greg.russell</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[bioscience]]></category>
		<category><![CDATA[Edinburgh]]></category>
		<category><![CDATA[ewing]]></category>
		<category><![CDATA[midlothian]]></category>
		<category><![CDATA[roslin]]></category>
		<category><![CDATA[science]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=252875</guid>
		<description><![CDATA[A YOUNG mother, who always wanted to work in science but lacked the confidence to pursue her dream career, is now a rising star in a Midlothian company which is a world leader in stem cell technology, thanks to the Modern Apprenticeship scheme and her own hard work. Twenty-nine-year-old Emma Clarke had spent her working ...]]></description>
		<wfw:commentRss>http://your-story.org/young-mum-is-a-science-star-252875/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Introduces New Microwave Peptide Synthesizer Delivering</title>
		<link>http://your-story.org/biotage-introduces-new-microwave-peptide-synthesizer-delivering-252632/</link>
		<comments>http://your-story.org/biotage-introduces-new-microwave-peptide-synthesizer-delivering-252632/#comments</comments>
		<pubDate>Wed, 13 Jul 2011 12:06:19 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[microwave peptide synthesizer]]></category>
		<category><![CDATA[peptide professionals]]></category>
		<category><![CDATA[peptide synthesis]]></category>
		<category><![CDATA[peptides]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=252632</guid>
		<description><![CDATA[Biotage introduced an innovative, new instrument for peptide professionals at the 2011 American Peptide Symposium in San Diego, California USA. Uppsala, Sweden, July 12, 2011 &#8212; Biotage® (STO: BIOT), a leading supplier of tools and technology for analytical, medicinal, and peptide chemistry, introduced an innovative, new instrument for peptide professionals at the 2011 American Peptide ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-introduces-new-microwave-peptide-synthesizer-delivering-252632/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Raises the Bar in Microwave Synthesis</title>
		<link>http://your-story.org/biotage-raises-the-bar-in-microwave-synthesis-251661/</link>
		<comments>http://your-story.org/biotage-raises-the-bar-in-microwave-synthesis-251661/#comments</comments>
		<pubDate>Fri, 08 Jul 2011 08:47:41 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[initiator+]]></category>
		<category><![CDATA[initiator+ synthesizer]]></category>
		<category><![CDATA[microwave synthesis]]></category>
		<category><![CDATA[microwave synthesizer]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=251661</guid>
		<description><![CDATA[Uppsala, Sweden, July 08, 2010 &#8212; Biotage® (STO: BIOT), a leading supplier of tools and technology for analytical, medicinal, and peptide chemistry, announced a new microwave synthesizer with state of the art user interface and industry leading operating range. The Biotage Initiator+ sets a new standard by delivering new opportunities for chemistry professionals needing to ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-raises-the-bar-in-microwave-synthesis-251661/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Chemical Plants Become More Efficient with Help from Intelligent Sensors</title>
		<link>http://your-story.org/chemical-plants-become-more-efficient-with-help-from-intelligent-sensors-250733/</link>
		<comments>http://your-story.org/chemical-plants-become-more-efficient-with-help-from-intelligent-sensors-250733/#comments</comments>
		<pubDate>Mon, 04 Jul 2011 14:38:56 +0000</pubDate>
		<dc:creator>Marie-Louise Hupert</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA["Chemical Plants]]></category>
		<category><![CDATA[chemical industry]]></category>
		<category><![CDATA[conductivity]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[downtime]]></category>
		<category><![CDATA[Intelligent Sensors]]></category>
		<category><![CDATA[measuring parameters"]]></category>
		<category><![CDATA[ORP]]></category>
		<category><![CDATA[pH]]></category>
		<category><![CDATA[substantial expenditure]]></category>
		<category><![CDATA[turbidity]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=250733</guid>
		<description><![CDATA[A large variety of processes, few of which are exactly alike, typical unit operations share many commonalities. One of these is the requirement for accurate process analytics in order to help maximize product quality and yield and to minimize costs. Measurement of pH, ORP, conductivity, DO or turbidity may seem like small parts of a ...]]></description>
		<wfw:commentRss>http://your-story.org/chemical-plants-become-more-efficient-with-help-from-intelligent-sensors-250733/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High Profile M&amp;As Steaming up Israeli Life Sciences Industry</title>
		<link>http://your-story.org/high-profile-mas-steaming-up-israeli-life-sciences-industry-250296/</link>
		<comments>http://your-story.org/high-profile-mas-steaming-up-israeli-life-sciences-industry-250296/#comments</comments>
		<pubDate>Fri, 01 Jul 2011 12:47:22 +0000</pubDate>
		<dc:creator>rncos</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Israel Life Sciences Company]]></category>
		<category><![CDATA[Israel Life Sciences Industry]]></category>
		<category><![CDATA[Israel Ph.D. Graduates]]></category>

		<guid isPermaLink="false">http://your-story.org/?p=250296</guid>
		<description><![CDATA[As per our new research report “Israel Life Sciences Market Analysis”, Israeli Life Science companies in general have witnessed impressive returns via IPOs, mergers, and acquisitions. It has been found in our research that, the value of M&#38;A’s and IPO’s in Israeli Life Sciences companies totaled US$ 822 Million in 2009. The main drivers for ...]]></description>
		<wfw:commentRss>http://your-story.org/high-profile-mas-steaming-up-israeli-life-sciences-industry-250296/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Announces Peptide Research Collaboration with the Laboratory of Peptide and Protein Chemistry and Biology in Florence, Italy</title>
		<link>http://your-story.org/biotage-announces-peptide-research-collaboration-with-the-laboratory-of-peptide-and-protein-chemistry-and-biology-in-florence-italy-245757/</link>
		<comments>http://your-story.org/biotage-announces-peptide-research-collaboration-with-the-laboratory-of-peptide-and-protein-chemistry-and-biology-in-florence-italy-245757/#comments</comments>
		<pubDate>Thu, 02 Jun 2011 10:43:36 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[peptide production]]></category>
		<category><![CDATA[peptide research]]></category>
		<category><![CDATA[peptlab]]></category>
		<category><![CDATA[research agreement]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=245757</guid>
		<description><![CDATA[Biotage (STO: BIOT), announced a collaborative research agreement with The Laboratory of Peptide &#38; Protein Chemistry &#38; Biology (PeptLab) located in Florence, Italy. Uppsala, Sweden, June 01, 2011 &#8212; Biotage (STO: BIOT), a leading supplier of tools and technology for analytical and medicinapl chemistry, announced a collaborative research agreement with The Laboratory of Peptide &#38; ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-announces-peptide-research-collaboration-with-the-laboratory-of-peptide-and-protein-chemistry-and-biology-in-florence-italy-245757/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Insight Pharma Reports Announces Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report</title>
		<link>http://your-story.org/insight-pharma-reports-announces-commercializing-biomarkers-in-therapeutic-and-diagnostic-applications-report-245702/</link>
		<comments>http://your-story.org/insight-pharma-reports-announces-commercializing-biomarkers-in-therapeutic-and-diagnostic-applications-report-245702/#comments</comments>
		<pubDate>Wed, 01 Jun 2011 20:04:29 +0000</pubDate>
		<dc:creator>InsightPharmaReports</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[diagnostic markets]]></category>
		<category><![CDATA[drug safety]]></category>
		<category><![CDATA[Market Research]]></category>
		<category><![CDATA[nerurology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Reports]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=245702</guid>
		<description><![CDATA[For more information: Lisa Scimemi Insight Pharma Reports 781-972-5446  FOR IMMEDIATE RELEASE Insight Pharma Reports Announces Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report  NEEDHAM, MASS.  – Cambridge Healthtech Institute’s Insight Pharma Reports announces the Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report, Authored by Lucy Sannes, MBA, PhD. Biomarkers feature in thousands of published articles each ...]]></description>
		<wfw:commentRss>http://your-story.org/insight-pharma-reports-announces-commercializing-biomarkers-in-therapeutic-and-diagnostic-applications-report-245702/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Introduces New Positive Pressure, Solid Phase Extraction Platforms for Increasing Productivity in Sample Preparation</title>
		<link>http://your-story.org/biotage-introduces-new-positive-pressure-solid-phase-extraction-platforms-for-increasing-productivity-in-sample-preparation-244610/</link>
		<comments>http://your-story.org/biotage-introduces-new-positive-pressure-solid-phase-extraction-platforms-for-increasing-productivity-in-sample-preparation-244610/#comments</comments>
		<pubDate>Thu, 26 May 2011 10:26:27 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[analytes]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[extraction platforms]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[sample preparation]]></category>
		<category><![CDATA[solid phase extraction]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=244610</guid>
		<description><![CDATA[Uppsala, Sweden, May 26, 2011 &#8212; Biotage® (STO: BIOT), a leading supplier of tools and technology for analytical and medicinal chemistry, announced 2 new instruments that utilize positive pressure for solid-phase extraction (SPE) of analytes in a wide variety of applications. The Biotage PRESSURE+ 96 processes 96-well SPE plates and the Biotage PRESSURE+ 48 processes ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-introduces-new-positive-pressure-solid-phase-extraction-platforms-for-increasing-productivity-in-sample-preparation-244610/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Introduces EVOLUTE WAX, Providing a Total Solution for Acidic Compounds</title>
		<link>http://your-story.org/biotage-introduces-evolute-wax-providing-a-total-solution-for-acidic-compounds-238869/</link>
		<comments>http://your-story.org/biotage-introduces-evolute-wax-providing-a-total-solution-for-acidic-compounds-238869/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 11:23:29 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[acidic analytes]]></category>
		<category><![CDATA[acidic compounds]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[evolute wax]]></category>
		<category><![CDATA[sample preparation products]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=238869</guid>
		<description><![CDATA[Uppsala, Sweden, April 20, 2011 &#8212; Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the further expansion of its successful family of sample preparation products with the launch of EVOLUTE WAX. EVOLUTE WAX is a mixed-mode weak anion exchanger, developed for the extraction of strongly acidic analytes from ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-introduces-evolute-wax-providing-a-total-solution-for-acidic-compounds-238869/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Discloses Interview on Therapeutic Strategies to Address Hepatitis C (HCV) and HIV</title>
		<link>http://your-story.org/biotechbiodefense-stock-news-aethlon-medical-otcbb-aemd-discloses-interview-on-therapeutic-strategies-to-address-hepatitis-c-hcv-and-hiv-238452/</link>
		<comments>http://your-story.org/biotechbiodefense-stock-news-aethlon-medical-otcbb-aemd-discloses-interview-on-therapeutic-strategies-to-address-hepatitis-c-hcv-and-hiv-238452/#comments</comments>
		<pubDate>Tue, 19 Apr 2011 23:25:53 +0000</pubDate>
		<dc:creator>Investorideas</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biodefense]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[stocks]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=238452</guid>
		<description><![CDATA[SAN DIEGO &#8211; April 15, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that InvestorIdeas.com has released an interview with Aethlon CEO Jim Joyce regarding broad spectrum treatment strategies to address HIV, Hepatitis C and other infectious disease conditions. The ...]]></description>
		<wfw:commentRss>http://your-story.org/biotechbiodefense-stock-news-aethlon-medical-otcbb-aemd-discloses-interview-on-therapeutic-strategies-to-address-hepatitis-c-hcv-and-hiv-238452/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Norton Scientific Continues Growth; Expands Distribution Network Into Asia</title>
		<link>http://your-story.org/norton-scientific-continues-growth-expands-distribution-network-into-asia-238212/</link>
		<comments>http://your-story.org/norton-scientific-continues-growth-expands-distribution-network-into-asia-238212/#comments</comments>
		<pubDate>Sat, 16 Apr 2011 12:51:00 +0000</pubDate>
		<dc:creator>nortonscientific</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[expansion]]></category>
		<category><![CDATA[measurement]]></category>
		<category><![CDATA[Norton]]></category>
		<category><![CDATA[prisma]]></category>
		<category><![CDATA[Scientific]]></category>
		<category><![CDATA[tools]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=238212</guid>
		<description><![CDATA[(Thorold) – Norton Scientific is proud to announce the company concluded a deal with Prisma Biotech of Taiwan and has ended its first quarter of the year on a very positive note. Bryan Webb, President of Norton, explains market acceptance of their PAM protein monitoring tool has increased dramatically since its introduction at PITTCON 2011 ...]]></description>
		<wfw:commentRss>http://your-story.org/norton-scientific-continues-growth-expands-distribution-network-into-asia-238212/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Oxford Expression Technologies Launches Optimized Insect Cell Transfection Reagent</title>
		<link>http://your-story.org/oxford-expression-technologies-launches-optimized-insect-cell-transfection-reagent-237510/</link>
		<comments>http://your-story.org/oxford-expression-technologies-launches-optimized-insect-cell-transfection-reagent-237510/#comments</comments>
		<pubDate>Sat, 09 Apr 2011 17:05:25 +0000</pubDate>
		<dc:creator>straightlinepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[baculoFECTIN]]></category>
		<category><![CDATA[DNA-binding]]></category>
		<category><![CDATA[Insect Cell]]></category>
		<category><![CDATA[Oxford Expression]]></category>
		<category><![CDATA[Transfection Reagent]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=237510</guid>
		<description><![CDATA[Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, has launched baculoFECTIN. Oxford, UK, April 04, 2011 &#8211; Oxford Expression Technologies, the award-winning specialist provider of baculovirus-based protein expression solutions, has launched baculoFECTIN. This new non-toxic transfection reagent has been optimized for use in insect cells and proven to produce greater levels ...]]></description>
		<wfw:commentRss>http://your-story.org/oxford-expression-technologies-launches-optimized-insect-cell-transfection-reagent-237510/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Norton Scientific Continues Expansion into US Market</title>
		<link>http://your-story.org/norton-scientific-continues-expansion-into-us-market-237103/</link>
		<comments>http://your-story.org/norton-scientific-continues-expansion-into-us-market-237103/#comments</comments>
		<pubDate>Tue, 05 Apr 2011 20:29:48 +0000</pubDate>
		<dc:creator>nortonscientific</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[bryan]]></category>
		<category><![CDATA[expansion]]></category>
		<category><![CDATA[Norton]]></category>
		<category><![CDATA[Scientific]]></category>
		<category><![CDATA[US market]]></category>
		<category><![CDATA[webb]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=237103</guid>
		<description><![CDATA[(Thorold) - In accordance with their sales growth strategy for North America, Brian Webb, President of Norton Scientific, is pleased to announce the company has concluded two sales representation deals with experienced professionals covering key customer clusters in New England and the Mid West.  These latest agreements extend sales coverage to include the main biotechnology clusters ...]]></description>
		<wfw:commentRss>http://your-story.org/norton-scientific-continues-expansion-into-us-market-237103/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Introduces Unique, Entry-Level System for Microwave-Assisted Peptide Synthesis</title>
		<link>http://your-story.org/biotage-introduces-unique-entry-level-system-for-microwave-assisted-peptide-synthesis-236046/</link>
		<comments>http://your-story.org/biotage-introduces-unique-entry-level-system-for-microwave-assisted-peptide-synthesis-236046/#comments</comments>
		<pubDate>Fri, 25 Mar 2011 12:00:46 +0000</pubDate>
		<dc:creator>staronepr</dc:creator>
				<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotage]]></category>
		<category><![CDATA[microwave]]></category>
		<category><![CDATA[peptide synthesis]]></category>
		<category><![CDATA[synthesis]]></category>
		<category><![CDATA[synthesizers]]></category>
		<category><![CDATA[workstation]]></category>

		<guid isPermaLink="false">http://www.your-story.org/?p=236046</guid>
		<description><![CDATA[Uppsala, Sweden, March 24, 2011 &#8212; Biotage® (STO: BIOT), a leading supplier of tools and technology for medicinal, analytical and peptide chemistry, introduced the Biotage Initiator Peptide Workstation for manual microwave-assisted peptide synthesis. The Workstation utilizes a unique microwave peptide vial available in two sizes; 2-5 mL for 75-150 µmol scale or 10-20 mL for ...]]></description>
		<wfw:commentRss>http://your-story.org/biotage-introduces-unique-entry-level-system-for-microwave-assisted-peptide-synthesis-236046/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Page Caching using disk: enhanced
Content Delivery Network via Amazon Web Services: CloudFront: d18wou7xwzd7x8.cloudfront.net

Served from: your-story.org @ 2012-02-14 22:19:20 -->
